InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: midastouch017 post# 1013

Thursday, 08/10/2017 6:56:21 PM

Thursday, August 10, 2017 6:56:21 PM

Post# of 3878
Well I have different opinion - you probably know that I am long and strong supporter of co and mgmt (in fact I consider this co mgmt to be one of the best team among all small biotechs I am invested)

However - the revenue generation capacity of the 2 drugs maybe limited to 8-10 million per quarter for at least 1 year - which is on higher side. The sales and marketing costs will be high and net benefit will be low.

The multiple trials will need much higher funding and the revenue will not support it. So dilution is coming.
The dilution is Ok with me but the long term cycle for test means the SP will be remain low.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News